Abstract 726P
Background
Patients with recurrent cervical cancer, especially those resistant to platinum-based chemotherapy, have limited treatment options. PD-1 blockade monotherapy stands out as one of the optimal choices in this context. PARP inhibition may exert an immune modulatory effect through the cGAS/STING pathway, and this phase II trial aims to explore the efficacy and safety of pembrolizumab (Pem) plus olaparib (Ola) in this patient cohort.
Methods
This multicenter investigator-initiated single-arm Phase II trial assesses the antitumor effects and survival outcomes of combining PD-1 inhibition with Pem and PARP inhibition with Ola. Eligible patients, who had prior platinum-based chemotherapies and no prior immunotherapy, received Pem (200mg every 3 weeks) and Ola (600mg per day) combination therapy until disease progression or unacceptable toxicity. The primary endpoint is objective response rate (ORR) by RECISTv1.1.
Results
Between June 2021 and July 2022, twenty-eight patients were enrolled. Patient characteristics included a median age of 55 years, with 14 (50%) patients having squamous cell carcinoma and 14 (50%) adenocarcinoma/adenosquamous carcinoma. Twenty-two (79%) patients had more than 2 lines of chemotherapy, and 22 (79%) patients had a history of bevacizumab. Twenty-six of 28 patients were evaluable for antitumor activity, as two patients did not have RECIST evaluation after treatment initiation. The ORR was 7.7% and the disease control rate was 53.8%. The median PFS and OS were 3.4 and 11.9 months, respectively. No patients required Pem discontinuation, but 4 (14%) patients required Ola discontinuation due to adverse events (AEs). All patients and 21 (75%) patients experienced any grade of AEs due to Ola or Pem, respectively. Grade≥3 AEs were observed in 17 (61%) patients, with anemia (29%) and decreased white blood cell counts (11%) being the most common.
Conclusions
This trial investigates Pem plus Ola combination therapy in platinum-experienced recurrent cervical cancer, revealing manageable safety. However, limited activity was observed with the addition of Ola to PD-1 inhibition in this study.
Clinical trial identification
NCT04641728. First posted November 24, 2020.
Editorial acknowledgement
Legal entity responsible for the study
Gynecologic Oncology Trial and Investigation Consortium (GOTIC).
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
640P - Tumor response rate for hematologic and solid cancer drugs with FDA approval supported by single-arm trials
Presenter: Daniel Michaeli
Session: Poster session 01
641P - Phase I/II clinical and pharmacokinetic study of ecubectedin in combination with irinotecan in patients with selected advanced solid tumors
Presenter: Ana Gil Torralvo
Session: Poster session 01
642P - Phase I study of SHR-A2009, a HER3-targeted ADC, in pretreated EGFR-mutated NSCLC
Presenter: Qing Zhou
Session: Poster session 01
644P - Preliminary results of GQ1005 in metastatic HER2-low expressing breast cancer and HER2 positive gastric cancer
Presenter: Ting Deng
Session: Poster session 01
645P - Persistence and resistance of HER2 amplification after T-DM1 in a basket trial for patients with solid tumors
Presenter: Dazhi Liu
Session: Poster session 01
646P - A phase I trial of AVA6000, a fibroblast activation protein (FAP)-released, tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors
Presenter: Christopher Twelves
Session: Poster session 01
Resources:
Abstract
647P - EphA2-targeting bicycle toxin conjugate (BTC) BT5528 in patients (pts) with advanced solid tumors: A phase I/II study
Presenter: Elisa Fontana
Session: Poster session 01
649P - Phase I study of SHR-A2102, a nectin-4 targeted ADC, in patients with advanced solid tumors
Presenter: Hua Zhong
Session: Poster session 01
650P - Initial results from a phase I/II study of BT7480, a novel nectin-4/CD137 bicycle tumor-targeted immune cell agonist, in patients (pts) with advanced solid tumors
Presenter: Kyriakos Papadopoulos
Session: Poster session 01